CTLA4 and neoplasm: Anti-CTLA-4 and anti-PD-L1 mAbs must bind activating FcγRs to exert potent anti-tumor activity by ADCC- or ADPC-mediated depletion of Tregs, or myeloid and tumor cells, respectively10,25,37–39.